Skip to content

LBRX LBRX Return on assets

Return on assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
8.1%+2.5pp
Alkermes logo
AlkermesALKS
4.8%-12.0pp
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
-52.3%
Alto Neuroscience logo
Alto NeuroscienceANRO
-33.2%+0.1pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
55.1%+36.5pp
Opko Health logo
Opko HealthOPK
-10.7%-13.6pp

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Calculated from LBRX’s reported figures.

Based on trailing twelve months.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's return on assets?
LBRX (LBRX) reported return on assets of -14.5% in Q4 2025.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.